| Features: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cinnamon is a spice from inner bark from several tree species. Cinnamon refers primarily to bark extracts from Cinnamomum verum (Ceylon cinnamon) and Cinnamomum cassia. Bioactive constituents include cinnamaldehyde, cinnamic acid derivatives, procyanidins, and polyphenols. In cancer models, cinnamon extracts and cinnamaldehyde are most frequently reported to exert anti-proliferative, pro-apoptotic, anti-inflammatory, and anti-angiogenic effects. Mechanistic themes include suppression of NF-κB and PI3K/AKT signaling, modulation of MAPK pathways, induction of mitochondrial apoptosis, and context-dependent ROS elevation in tumor cells. Some studies report inhibition of HIF-1α and glycolytic signaling, though cinnamon is not a direct enzymatic Warburg inhibitor. Effects vary substantially depending on species (Ceylon vs Cassia), preparation (aqueous vs ethanol extract), and dose. Human oncology data remain limited and largely preclinical. -Cinnamaldehyde (CA), an active compound derived from the natural plant cinnamon. CA is an aromatic aldehyde compound, constituting approximately 65% of cinnamon extract - See also HCA, a derivative of CA Biological activity, cinnamaldehyde from Ceylon cinnamon: Antimicrobial activity: 10-50 μM Antioxidant activity: 10-100 μM Anti-inflammatory activity: 20-50 μM Anticancer activity: 50-100 μM Cardiovascular health: 20-50 μM 5 g of Ceylon cinnamon might contain roughly between 30 mg and 150 mg of cinnamaldehyde, with an approximate mid-range estimate of about 70 mg. Assuming a moderate supplemental intake 50–200 mg of cinnamaldehyde, peak plasma levels might be anticipated in the vicinity of 1–10 μM. Primary mechanisms (ranked):
Bioavailability / PK relevance: Cinnamon is compositionally variable; cinnamaldehyde is lipophilic, rapidly absorbed and metabolized, and systemic exposure after oral intake is likely much lower than many in-vitro anticancer concentrations. Extract formulation, species, dose, food matrix, and first-pass metabolism materially affect exposure. In-vitro vs systemic exposure relevance: Many anticancer studies use extract concentrations or cinnamaldehyde levels that may exceed achievable free systemic exposure after ordinary oral intake. Local gastrointestinal exposure may be more plausible than systemic tumor exposure. Clinical evidence status: Preclinical for oncology. Cinnamon has human RCT/meta-analysis literature mainly in metabolic/inflammatory endpoints, but no established clinical anticancer indication. Translational constraints include variable extract chemistry, cassia coumarin hepatotoxicity risk, CYP/herb-drug interaction potential, and uncertain tumor-achievable exposure. Cinnamon Cancer Mechanism Table
TSF: P = 0–30 min (redox and early signaling effects), R = 30 min–3 hr (acute pathway modulation), G = >3 hr (apoptosis, angiogenesis, phenotype changes). |
| Source: |
| Type: transcription factor |
| Nrf1 (Nuclear factor erythroid 2-related factor 1) is a transcription factor that plays a crucial role in regulating cellular responses to stress, including oxidative stress and proteotoxic stress. While Nrf1 is generally considered a tumor suppressor, its expression and activity can be altered in various types of cancer, leading to either oncogenic or tumor-suppressive effects. NRF1, together with related factors like NRF2, contributes to the cellular defense against oxidative damage by regulating antioxidant gene expression. – This role can be double-edged: while it protects normal cells from damage, in cancer cells, enhanced antioxidant capacity might foster resistance to therapeutic agents that rely on oxidative stress to kill tumor cells. |
| 6144- | Cin, | The Cinnamon-Derived Dietary Factor Cinnamic Aldehyde Activates the Nrf2-Dependent Antioxidant Response in Human Epithelial Colon Cells |
| - | in-vitro, | Colon, | HCT116 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:62 Target#:878 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid